|
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov. |
NIDA-CSP-1033
Division
HEAL Study
Investigator(s)
Title
Phase 2, Multi-Center Trial of Lorcaserin in the Treatment of Cocaine Use Disorder
Short Description
The objective of this study is to evaluate the efficacy and safety of lorcaserin in the treatment of cocaine use disorder.
Release Date
Jul 19, 2024
Description
This is a 19-week, multi-center, parallel group study that includes: 1) up to 3
weeks for screening; 2) a 13-week Treatment Phase consisting of a 1-week, single-blind run-in
period, when all subjects receive twice daily 15 mg acetazolamide capsules (a medication
adherence marker), followed by randomization to either twice daily 10 mg lorcaserin or placebo
capsules for the remaining 12 weeks; and 3) a 3-week follow-up period, with scheduled visits
during Study Weeks 14 and 16.
Keywords
Accessibility Notice
Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.